$2.94
0[0.00%]
Last update: 5:18PM Get Real Time Here
Trevi Therapeutics
(NASDAQ:TRVI)Trevi Therapeutics Stock (NASDAQ:TRVI), Analyst Ratings, Price Targets, Predictions
Trevi Therapeutics Inc has a consensus price target of $7.67, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from Needham, Oppenheimer, and Needham on April 9, 2024, March 21, 2024, and March 21, 2024. With an average price target of $8.33 between Needham, Oppenheimer, and Needham, there's an implied 183.45% upside for Trevi Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Oppenheimer
B. Riley Securities
JonesTrading
SVB Leerink
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Trevi Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 206.12% | Oppenheimer | Leland Gershell | $9 → $9 | Maintains | Outperform | Get Alert |
| 03/21/2024 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | → Buy | Get Alert |
| 04/12/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 104.08% | B. Riley Securities | Mayank Mamtani | → $6 | Initiates | → Buy | Get Alert |
| 03/17/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | → $8 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 138.1% | JonesTrading | Sean Kim | → $7 | Initiates | → Buy | Get Alert |
| 11/22/2022 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 104.08% | SVB Leerink | Thomas Smith | → $6 | Initiates | → Outperform | Get Alert |
| 11/11/2022 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | $10 → $8 | Maintains | Buy | Get Alert |
| 06/30/2022 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 240.14% | Needham | Serge Belanger | $8 → $10 | Maintains | Buy | Get Alert |
| 05/25/2022 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 240.14% | Oppenheimer | Leland Gershell | → $10 | Initiates | → Outperform | Get Alert |
| 03/29/2022 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 240.14% | Aegis Capital | Nathan Weinstein | → $10 | Initiates | → Buy | Get Alert |
| 11/11/2021 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 172.11% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
| 08/13/2021 | TRVI | Buy Now | Trevi Therapeutics | $2.94 | 240.14% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Trevi Therapeutics (TRVI)?
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by Needham on April 9, 2024. The analyst firm set a price target for $8.00 expecting TRVI to rise to within 12 months (a possible 172.11% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Trevi Therapeutics (TRVI)?
The latest analyst rating for Trevi Therapeutics (NASDAQ: TRVI) was provided by Needham, and Trevi Therapeutics reiterated their buy rating.
When was the last upgrade for Trevi Therapeutics (TRVI)?
There is no last upgrade for Trevi Therapeutics.
When was the last downgrade for Trevi Therapeutics (TRVI)?
There is no last downgrade for Trevi Therapeutics.
When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Trevi Therapeutics (TRVI) correct?
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Trevi Therapeutics (TRVI) is trading at is $2.94, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.